Clinical trials: Stage II/III Colon Cancer
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Postoperative Stage II/III Colon Cancer
Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer
The purpose of this study is to evaluate the efficacy and safety of ART-123 for the prevention of cancer treatment related symptoms in patients with postoperative stage II / III colon cancer.
- Trial name
- NCT02792842
- Testing
- ART-123 (3-day ART), ART-123 (1-day ART)
- Where
- 2 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Colorectal Cancer
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
RATIONALE: Drugs used in chemotherapy, such as DJ-927, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080834
- Testing
- DJ-927
- Where
- 2 sites in United States
- Sponsor
- Daiichi Sankyo
Metastatic Colorectal Cancer
Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer
The primary purpose of this study is to evaluate the clinical response and safety of CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type…
- Trial name
- CRC009 (NCT01550055)
- Testing
- CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009
- Volunteers
- 512 people
- Sponsor
- Shanghai Zhangjiang Biotechnology Limited Company
Stage II/III Colon Cancer, Bowel Cancer
Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer
TThis study evaluates the safety and effectiveness of pre-operative artesunate, given orally once a day for 14 days prior to surgery, in patients with Stage II/III colorectal cancer.
- Trial name
- NeoART-M (NCT07095309)
- Testing
- Artesunate
- Where
- 6 sites in Malaysia
- Volunteers
- 120 people
- Sponsor
- Metanoic Health Ltd.
Colorectal Cancer
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112918
- Testing
- Bevacizumab, Capecitabine, 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 3,451 people
- Sponsor
- Hoffmann-La Roche
Stage II Colon Cancer, Stage III Colon Cancer
Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer
According to general medical guidelines, adjuvant chemotherapy is used after curative resection of high-risk stage II or III primary colon cancer.
- Trial name
- OCEAN (NCT04416490)
- Where
- South Korea
- Volunteers
- 2,013 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
CRC (Colorectal Cancer)
A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy
The purpose of this study is to evaluate INCA33890 in the treatment of circulating tumor DNA-positive stage II/III microsatellite stable colorectal cancer after curative resection and chemotherapy.
- Trial name
- NEXERA-204 (NCT07823322)
- Testing
- INCA33890
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Gastrointestinal Cancer, Prostate Cancer
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response.
- Conditions
- Gastrointestinal Cancer, Prostate Cancer, Genital Neoplasms, Female
- Trial name
- NCT00332280
- Testing
- AMT2003
- Where
- 2 sites in Bosnia and Herzegovina, Germany
- Volunteers
- 67 people
- Sponsor
- Auron Healthcare GmbH
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
This is a multi-site epidemiological study designed to monitor circulating tumor DNA (ctDNA) status in participants with Stage II (high risk)/III colorectal cancer (CRC) following resection/prior to adjuvant chemotherapy (AdCTx)…
- Trial name
- NCT04813627
- Testing
- Regular blood sample collection for ctDNA assessment
- Where
- 74 sites in United States, Belgium and 2 more
- Volunteers
- 2,079 people
- Sponsor
- BioNTech SE
Colorectal Cancer
Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00007826
- Testing
- BCG vaccine, monoclonal antibody 105AD7 anti-idiotype vaccine, alum adjuvant
- Where
- United Kingdom
- Sponsor
- Onyvax